Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mirebeau, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mirebeau, D
Haematologica, Vol 91, Issue 7, 881-885
Copyright © 2006 by Ferrata Storti Foundation


Journal Article

The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951

D Mirebeau, C Acquaviva, S Suciu, R Bertin, N Dastugue, A Robert, P Boutard, F Mechinaud, E Plouvier, J Otten, E Vilmer, H Cave, and

AP-HP, Paris, France.

BACKGROUND AND OBJECTIVES: Deletion and methylation of the 9p21 chromosomal region are frequent in childhood acute lymphoblastic leukemia (ALL) but the prognostic significance is controversial. They inactivate CDKN2A, a gene encoding both p16INKa and p14ARF and, in some cases, contiguous genes that may influence chemosensitivity, such as CDKN2B encoding p15INKb or MTAP encoding methylthioadenosine phosphorylase. DESIGN AND METHODS: CDKN2A inactivation by deletion or methylation was studied using gene dosage and methyl-specific polymerase chain reaction. RESULTS: Bi-allelic and mono-allelic inactivation were found in, respectively, 38 (17%) and 31 (14%) of 227 children with B-lineage ALL enrolled in EORTC trials. Although CDKN2A inactivation was more often associated with poor prognostic features in B-lineage ALL, it failed to influence the outcome of the patients significantly. Bi-allelic CDKN2B and MTAP co-inactivation were found in 36 (16%) and 24 (11%) of patients, respectively, and did not influence the 6-year event-free survival rate either, even when the analysis was restricted to CDKN2A inactivated ALL. INTERPRETATION AND CONCLUSIONS: In this study of 227 cases of childhood B-lineage ALL, inactivation of CDKN2A, CDKN2B and MTAP did not influences the patients' outcome.


This article has been cited by other articles:


Home page
BloodHome page
L. J. Russell, T. Akasaka, A. Majid, K.-j. Sugimoto, E. Loraine Karran, I. Nagel, L. Harder, A. Claviez, S. Gesk, A. V. Moorman, et al.
t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Blood, January 1, 2008; 111(1): 387 - 391.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.